Brokers

Brokers Issue Forecasts for Pharming Group’s FY2026 Earnings (NASDAQ:PHAR)


Pharming Group (NASDAQ:PHARGet Rating) – Equities researchers at Oppenheimer raised their FY2026 earnings per share estimates for Pharming Group in a note issued to investors on Thursday, May 12th. Oppenheimer analyst H. Singh now expects that the company will earn $0.06 per share for the year, up from their previous forecast of $0.05.

Separately, Zacks Investment Research lowered Pharming Group from a “hold” rating to a “sell” rating in a report on Tuesday, March 29th.

PHAR stock opened at $8.05 on Monday. The company has a quick ratio of 4.75, a current ratio of 5.33 and a debt-to-equity ratio of 0.72. The business has a 50 day moving average of $8.52 and a 200-day moving average of $8.73. Pharming Group has a 12-month low of $6.71 and a 12-month high of $12.56.

Pharming Group (NASDAQ:PHARGet Rating) last issued its quarterly earnings data on Thursday, March 17th. The company reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. The company had revenue of $52.77 million for the quarter, compared to the consensus estimate of $57.59 million.

Several hedge funds have recently added to or reduced their stakes in the company. Cowen Prime Advisors LLC lifted its stake in Pharming Group by 134.9% in the fourth quarter. Cowen Prime Advisors LLC now owns 14,800 shares of the company’s stock valued at $132,000 after purchasing an additional 8,500 shares during the last quarter. Jane Street Group LLC lifted its stake in Pharming Group by 37.6% in the third quarter. Jane Street Group LLC now owns 17,441 shares of the company’s stock valued at $164,000 after purchasing an additional 4,767 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Pharming Group by 5,208.3% in the second quarter. Morgan Stanley now owns 2,548 shares of the company’s stock valued at $29,000 after purchasing an additional 2,500 shares during the last quarter. 0.03% of the stock is owned by institutional investors.

About Pharming Group (Get Rating)

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.

Read More



Receive News & Ratings for Pharming Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pharming Group and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.